The overall objective of the Program is to understand how chronic inflammation contributes to tumor promotion and progression. The current program will address several aspects of injury/pathogen-initiated signaling pathways focusing upon TLRs, the involvement of altered transcriptional and post-transcriptional control, and the causal links between inflammatory signaling and neoplasia. A major component that links three of the projects involves much expanded utilization of mouse genetics and mouse models of inflammatory disease and carcinogenesis. In each of project 1, 3 and 4, new transgenic mice will be generated, characterized and tested in several models of in vivo inflammatory response. A central focus of these studies will be the use of the mouse model of DSS colitis and its linkage with colon tumorigenesis. This central activity will be coordinated by the newly propose Core B (Mouse Colitis and Colitis-associated Cancer Analysis Core). The colitis analysis portion ofthis Core's primary objective is to set up a colitis model induced by DSS, TNBS or adoptive transfer and provide technical assistance in the analysis of the colitis symptoms, states of homeostasis and inflammation induced in transgenic mice produced by projects. The colitis-associated cancer portion ofthis core's primary objective is to set up the AOM+DSS-indueed CAC model and provide specific technical assistance in phenotype analyses (including tumor number, tumor size, histology analysis and other assays). Standardization of the protocols, evaluation and quantitative assays of colitis and tumorigenesis will facilitate inter-laboratory collaboration and data comparisons.

Public Health Relevance

This activity will standardize the protocols, evaluation and quantification assays for colitis and colitis- associated cancer models, so that consistent results will be obtained across the projects.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cleveland Clinic Lerner
United States
Zip Code
Chattopadhyay, Saurabh; Sen, Ganes C (2014) Meet the terminator: The phosphatase PP2A puts brakes on IRF-3 activation. Mol Cell 54:210-1
Dermawan, Josephine Kam Tai; Gurova, Katerina; Pink, John et al. (2014) Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-?B, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 13:2203-14
Zhao, Chenyang; Pavicic Jr, Paul G; Datta, Shyamasree et al. (2014) Cellular stress amplifies TLR3/4-induced CXCL1/2 gene transcription in mononuclear phagocytes via RIPK1. J Immunol 193:879-88
De, Sarmishtha; Dermawan, Josephine Kam Tai; Stark, George R (2014) EGF receptor uses SOS1 to drive constitutive activation of NF?B in cancer cells. Proc Natl Acad Sci U S A 111:11721-6
Yu, Minjia; Zhou, Hao; Zhao, Junjie et al. (2014) MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases. J Exp Med 211:887-907
Chattopadhyay, Saurabh; Sen, Ganes C (2014) dsRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects. J Interferon Cytokine Res 34:427-36
Chattopadhyay, Saurabh; Sen, Ganes C (2014) Tyrosine phosphorylation in Toll-like receptor signaling. Cytokine Growth Factor Rev 25:533-41
Stahl, Martin; Ries, Jenna; Vermeulen, Jenny et al. (2014) A novel mouse model of Campylobacter jejuni gastroenteritis reveals key pro-inflammatory and tissue protective roles for Toll-like receptor signaling during infection. PLoS Pathog 10:e1004264
Lin, Keng-Mean; Hu, Wei; Troutman, Ty Dale et al. (2014) IRAK-1 bypasses priming and directly links TLRs to rapid NLRP3 inflammasome activation. Proc Natl Acad Sci U S A 111:775-80
Dasgupta, Maupali; Unal, Hamiyet; Willard, Belinda et al. (2014) Critical role for lysine 685 in gene expression mediated by transcription factor unphosphorylated STAT3. J Biol Chem 289:30763-71

Showing the most recent 10 out of 210 publications